ANALYSIS: With an Obermatt 360° View of 86 (better than 86% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Xeris Pharmaceuticals are very positive. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Xeris Pharmaceuticals. The consolidated Value Rank has an attractive rank of 70, which means that the share price of Xeris Pharmaceuticals is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 70% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 92, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 43. Professional investors are more confident in 57% other stocks. Worryingly, the company has risky financing, with a Safety rank of 41. This means 59% of comparable companies have a safer financing structure than Xeris Pharmaceuticals. ...read more